Keyword: Harvard University
Feng Zhang's latest CRISPR company, Beam Therapeutics, officially came out of stealth Monday with $87 million in series A funding.
The past week ushered in news of a drug that reverses the decline of intestinal stem cells, a CAR-T for colorectal cancer and more.
The Sino-American startup thinks it can detect cell-free DNA in blood plasma and thereby enable screening for early-stage disease.
Amgen joined with MP Healthcare Venture Management and Alexandria Venture Investments to put the latest tranche of funding into QurAlis.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
A Harvard-led research team has identified a brain protein that exacerbates memory loss with age or PTSD.
Inscripta offers its CRISPR enzymes for free, but the biotech plans to make its money selling CRISPR tools.
Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.
Researchers at Massachusetts Eye and Ear have found a group of blood-based biomarkers that could improve diagnosis and treatment for AMD.
Harvard University researchers have identified an enzyme that protects cells from harmful fats, which could inform new obesity treatments.
